Antigenicity and Immunogenicity of Stabilized prefusion F protein

免疫原诱导的保护性，疾病保留CD 8 + T细胞反应是VRC研究工作的主要重点。这些研究旨在确定将提高基于核酸和载体的免疫接种效率的干预措施，并优化每种干预措施的条件。 将使用鼠初免-激发模型比较由每种载体诱导的免疫应答的幅度和质量。 RSV F糖蛋白是疫苗诱导的中和抗体的关键靶标。我们的假设是，通过定义F的结构和与中和相关的表位的结构，将有助于理解抗体中和的机制。这将允许新的抗原设计。表征F中的化学和翻译后修饰也将促进改进的疫苗抗原设计。 我们已经将我们稳定的融合前F蛋白推进到1期临床试验VRC 317的临床评价中。 在这项试验中，我们正在评估我们的稳定的融合前F蛋白（DS-Cav 1）与或与明矾佐剂在健康成人中的安全性，耐受性和免疫原性。

Immunogens inducing protective, disease-sparing CD8+ T cell responses are a primary focus of research efforts at the VRC. These studies are designed to identify interventions that will increase the efficiency of nucleic acid and vector-based immunization and to optimize the conditions of each intervention. The magnitude and the quality of the immune responses induced by each vector will be compared using murine prime-challenge models. The RSV F glycoprotein is a key target for vaccine-induced neutralizing antibody. Our hypothesis is that understanding the mechanism of antibody neutralization will be facilitated by defining the structure of F and the structure of epitopes associated with neutralization. This will allow novel antigen design. Characterizing the chemistry and post-translational modifications in F will also promote improved vaccine antigen design. We have advanced our stabilized prefusion F protein into clinical evaluation in a Phase 1 clinical trial, VRC 317. In this trial, we are evaluating safety, tolerability, and immunogenicity of our stabilized prefusion F protein (DS-Cav1) with or with alum adjuvant in healthy adults.